home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Promoting and Advertising Dietary Supplements in Compliance with FDA and FTC Regulations

 
  May 03, 2012  
     
 
ComplianceOnline, Online Webinar
2012-06-13


Why Should You Attend:

FDA and FTC routinely initiate enforcement actions, including Untitled Letters, Warning Letters, Recalls, etc., against dietary supplement makers who misbrand their products by violating FDA advertising and promotion regulations, e.g., by claiming the product can treat, cure, prevent, mitigate or diagnose disease. Sometimes the Department of Justice gets involved and prosecutes firms on behalf of these agencies for violations. Such prosecutions often involve lawsuits against individuals running the companies, and can lead to Consent Decrees for the companies and their owners and responsible corporate officers. These threats can be avoided with proper review of promotional materials and by training and educating staff.

  • Is your organization in compliance with FDA advertising and promotion regulations?
  • Is FDA investigating your firm right now?
  • Is your competitor blowing the whistle on you?
This webinar will review the applicable regulations, walk you through real-life case studies, help you address compliance, and tell you how to respond to an enforcement action. You will have opportunities to ask questions.

Learning Objectives:

At the end of this presentation, participants will

  • Learn how to distinguish a violative claim from a lawful one
  • Understand FDA and FTC regulations that govern what you can say about your products
  • Know what to do if FDA contacts you or pays a visit
  • Learn how to get started with a compliance program
 
 
Organized by: ComplianceOnline
Invited Speakers: Mark Gardner, M.B.A., J.D., is an attorney at DuVal & Associates, P.A., a law firm dedicated to counseling companies in the dietary supplement, medical device, drug, biotech and food industries.

His practice focuses on FDA regulation, health care fraud and compliance, design and implementation of regulatory compliance programs, promotional review, and FDA enforcement actions.
 
Deadline for Abstracts: 2012-06-13
 
Registration:
For Registration:- 
 
E-mail: referral@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.